Oral administration of xenobiotics is preferable for research in in vivo models because it mimics the real life situation of human subjects. Therefore, oral (po) monocrotaline (MCT) (a common contaminant of dietary supplements)/intraperitoneal (ip) lipopolysaccharides (LPS)-induced liver injury possibly imitates idiosyncratic hepatotoxicity in humans. Cytokines, for example interleukin-1β (IL-1β) and transforming growth factor beta (TGF-β) are known to play a role in the development of toxicity and repair processes, respectively. The purpose of this study was to develop and characterize a model of po MCT/ip LPS hepatotoxicity which may elucidate the mechanisms of injury. ND4 male mice were given MCT (200 mg/kg) followed 4 h later by LPS (6 mg/kg). Blood samples were drawn for plasma chemistry and IL-1β. Animals were euthanized and livers were harvested at different time points. We have shown that MCT/LPS cotreatment results in significant elevation of plasma alanine aminotransferase (ALT), CRP, IL-1β and TGF-β. Histopathological evaluation revealed diffuse degenerative injury. In summary, we have established a reproducible in vivo model of hepatotoxicity by po MCT/ip LPS cotreatment that may closely mimic real life idiosyncratic hepatotoxicity.
Animal studies serve as a valuable tool to study human diseases provided they faithfully simulate the precipitating conditions associated with these diseases, including the routes of exposure. The oral route is the most common one for food and drug uptake as it is convenient and usually the safest and least expensive. Humans and animals are exposed to hepatotoxic xenobiotics, including pyrrolizidine alkaloids (PAs), by accidental ingestion of herbal supplements contaminated with Crotalaria species [1a] . Monocrotaline is a cytotoxic, genotoxic and hepatotoxic PA and has been reported as a contaminant of dietary supplements [1b] . Hepatotoxicity from numerous xenobiotic agents is exaggerated by mild inflammatory stress caused by a variety of inflammagens, such as LPS [1c] . Clinical chemistry and histopathology data can be important proof-of-concept in animal hepatotoxicity models and provide a cornerstone in a general toxicology program. Accordingly, the rare idiosyncratic hepatotoxicity is manifested by elevation of aminotransferases and histopathological features of acute hepatocellular necrosis and/or biliary injury [1d,1e] .
Intraperitoneal MCT/LPS administration induces hepatotoxicity characterized by elevation of plasma liver-specific enzyme ALT, and liver parenchymal damage confirmed by histopathology. [1a,1c,2a] . C-reactive protein (CRP) is a widely used classical nonspecific but sensitive plasma protein marker of inflammation and/or acute phase responses. IL-1β is a proinflammatory cytokine, and its level is known to be increased during hepatotoxicity [2b] . CRP is known to increase production of IL-1β in peripheral blood mononuclear cells [2c] . Conversely, IL-1 β induces CRP release in human adipocytes [3] and synthesis of collagen in fibroblast cells [4] . TGF-β is the master cytokine in the pathogenesis of liver fibrosis and is secreted by chronically damaged hepatocytes [5a]. Collectively, CRP, IL-1β and TGF-β play a significant role in fibrogenesis and inflammation.
To our knowledge, no investigations have been reported on MCT/LPS induced hepatotoxicity by using an oral route of administration for MCT. Therefore, a compelling question arises whether po administration of MCT and ip injection of LPS would produce hepatotoxicity. In this study, we have successfully produced an in vivo hepatotoxicity model with po MCT and ip LPS. In doing so, we also selected to measure the levels of IL-1β as one of the early inflammatory cytokines, CRP as an inflammatory biomarker, and TGF-β as a key cytokine that mediates fibrotic changes during the course of hepatic injury in this model.
Characterization of po MCT/ip LPS-induced liver injury
Clinical chemistry: MCT/LPS cotreatment increased ALT activity 17-fold, 25-fold, 36-fold and 43-fold compared with vehical treated mice at 13, 16, 18 and 24 h, respectively ( Figure 1 ). Animals treated with a higher dose of MCT (300, 400 and 600 mg/kg) and LPS (8, 10 and 12 mg/kg) died within 24 h (data not shown); therefore, 200 MCT mg/kg and 6 LPS mg/kg were selected for all subsequent studies. Twenty-four hours was selected as an end point for the dose response experiments described above. Mice were sacrificed at 10-24 h after MCT treatment and blood ALT was measured ( Figure 1 ). From 0 to 10 h, there was no significant increase in ALT (data not presented). On the other hand, Figure 2 shows that the mean CRP plasma level in vehicle treated mice was 16 ± 2 and 22 ± 0.5 ng/dl at 10 and 24 h, respectively. MCT and/or LPS treatment led to an approximately two fold increase in CRP levels at 10 h and returned to basal level at 24 h.
Histopathological examination of the liver:
Histopathological evaluation of liver sections at 10 and 24 hours after respective treatments is shown in Figure  3 . Livers from vehicle, MCT and LPS treated mice showed no histopathological changes. However, those from the MCT/LPS-cotreated mice showed necrosis in midzonal, pericentral and periportal regions, accompanied by fatty changes. In addition, these liver sections showed hemorrhage with loss of sinusoidal architecture upon MCT/LPS cotreatment. These sinusoids were dilated and congested with blood. Other hepatocellular changes noted were microvesicular steatosis, apoptotis and necrosis ( Figure 3 ). Plasma concentrations of IL-1β: Levels of IL-1β were evaluated in the serum of MCT and/or LPS and vehicle treated mice at 10 and 24 h after treatment. As shown in Figure 4 , plasma IL-1β level of MCT/LPS co-treated mice significantly increased at 10 h (110 ±30 pg/mL) and declined at 24 h (60 ±10 pg/mL), but remained significantly higher compared with the vehicle and MCT treated groups.
TGF-β expression in liver sections of MCT/LPS cotreated mice:
To investigate the expression of TGF-β in this model of liver toxicity, we performed immunofluorescence analysis of TGF-β in liver sections at two different time-points after the treatments. As shown in Figure 5 , MCT and LPS treatments showed a basal level of TGF-β at 10 or 24 h. MCT/LPS cotreatment showed significant TGF-β expression at 10 and 24 h. This expression was observed in the necrotic area, compared with that with other treatments. Figure  5B also shows a rising trend in TGF-β expression from 10 to 24 h in the liver sections of MCT/LPS co-treated mice. Representative micrographs of liver sections from mice at 10 and 24 h after various treatments, as described in the Experimental. No remarkable lesion was seen except in the MCT/LPS co-treated group, where pronounced vacuoles (arrow head), hemorrhage (arrows) and apoptosis/necrosis (stars) were observed at 24 h. The present study demonstrates for the first time a mouse model to study the likelihood of oral administration of MCT (200 mg/kg, po) and LPS (6 mg/kg, ip) to generate liver injury. In the preliminary studies, the adopted time course (MCT followed after 4 h by LPS) was found to be the only optimal design to produce hepatotoxicity. This could indeed be due to the priming effect of the subtoxic dose of MCT on liver cells synergized by the subinflammatory dose of LPS leading to fulminant hepatotoxicity.
Our results with poMCT/ipLPS showed hepatotoxicity similar to that shown in previous study with ipMCT/ipLPS [5b]. However, a relatively higher dose of MCT was required by the oral route to produce the same effect. MCT/LPS co-treatment significantly elevated ALT level, while individual treatments of MCT, LPS and vehicle did not change it. Histopathological changes (hemorrhage, fatty change and necrosis/apoptosis) in MCT/LPS co-treated animals reported here coincide with a previous report [1e]. The current data support the hypothesis that microvascular injuries play a central role in the mechanism of MCT/LPS-induced liver injury. CRP is mainly expressed by hepatocytes, and its synthesis is regulated at the posttranscriptional level by cytokines [5c]. Its concentration rises in the plasma in acute inflammatory conditions up to a thousandfold [6a] . CRP's main function is to boost the inflammatory response by assisting the generation of proinflammatory cytokines [6b]. A very high level of CRP is used mainly as a marker of vascular inflammation, a valuable predictor and prognostic marker for vascular diseases such as CVD events [6c]. The current study was the first to consider CRP expression as a diagnostic marker in MCT/LPS-induced hepatotoxicity. There was a transient significant rise in CRP plasma level in MCT and/or LPS cotreated groups compared with the vehicle treated group at 10 h; however, it returned to basal level at 24 h. A similar observation was reported by Oruc et al. [6d] and contradicted by Aronson et al. [6e] in other liver pathological conditions. Accordingly, our current observations suggest that CRP provides insufficient information on the progress of inflammation and severity of liver dysfunction, thus has a poor diagnostic and prognostic value for hepatotoxicity in the current MCT/LPS co-treatment model. One plausible explanation is that CRP may have fast kinetics; therefore, it reacts and recesses quickly during the course of inflammation.
Our findings also implicated IL-1β as an upstream signal induced at an early stage of liver injury, as formerly reported [2b] . MCT/LPS co-treated mice had significantly increased plasma IL-1β and ALT levels at 10 and 24 h. However, at 24 h, the IL-1β level was lower than that at 10 h. A previous report [6f] agrees with our present results indicating that plasma levels of IL-1β may be a key player that drive the initial stages of the hepatoinflammatory condition represented by high ALT blood level. Furthermore, the induction of plasma IL-1β may partially augment plasma CRP, as observed earlier [7a] . TGF-β is a profibrogenic mediator secreted by Kuppfer cells (KCs), hepatic stellate cells (HSCs) and hepatocytes (HPCs) [7b]. It is involved in controlled healing following acute injury. However, it acts as a principal promoter of scarring in chronic ones [8a] . In the liver, its fibrogenic effect can be attributed to an enhanced transdifferentiation of HSCs to myofibrobalsts (MFB) producing extracellular matrix (ECM) [8b]. Thus, it plays a crucial role in the remodeling processes of the liver [9a] . Moreover, when over-expressed, it contributes to hepatotoxicity by injuring HPCs and consequently inducing cell death under pathological conditions [9b] . Also, a significant direct positive correlation between TGFβ and CRP has been reported in obese healthy subjects [10a] . In addition, CRP synthesis in HPCs is regulated by TGF-β at the post-transcriptional level [10b]. However, in the present hepatotoxicity model, this regulation was not observed. Analysis of inflammed mucosal tissues disclosed increased levels of IL-1β and TGF-β [10c]. In the current study, a declining trend of induced IL-1 β and a rising trend of TGF-β from 10 to 24 h may be indicative of the attempt of the liver to recover from ongoing inflammatory injury.
In summary, our findings suggest a model for understanding idiosyncratic hepatotoxicity by using an oral route of administration for xenobiotics. Elevation of plasma ALT remains the hallmark of liver damage. Histopathological lesions included perivascular and midzonal hemorrhage and focal necrosis/apoptosis. In addition, microvesicular steatosis in the midzonal region was observed. In this model, there was initial induction of both IL-1β and TGF-β, followed by a decline in the former and a rise in the latter. CRP did not appear to be a sensitive marker and did not reflect pathological changes in the liver.
Experimental
Treatment protocol and study design Animal model: Male ND-4 mice were obtained from Harlan Lab (Indianapolis, IN) at 5 weeks of age and 21-24 g of weight upon receipt, housed in micro isolator cages with corn cob bedding, on 12 h light/dark cycle, at 72°F temperature and 35-50% relative humidity. Mice were fed on Purina 5001 laboratory chow and water ad libitum. Prior to the experiment, mice were fasted for 12 h and randomly assigned into 4 groups. MCT/ vehicle (Veh.): MCT (po) followed after 4 h by saline (ip), Veh.-LPS: saline (po) followed after 4 h by LPS (ip), MCT-LPS: MCT (po) followed after 4 h by LPS (ip) and Veh.-Veh.: Saline (po) followed after 4 h by saline (ip). Following the above treatments, food was made available ad libitum. Initial studies were performed to evaluate the dose-response and temporal relationship between MCT and LPS liver injury. In the dose-response study,, liver injury was assessed 10 and 24 h after MCT administration at doses ranging from 100 to 400 mg/kg (MCT) and from 0.5 to 8 mg/kg (LPS). MCT and LPS were both given in a volume of 100 uL per mouse at the indicated doses. All animal study protocols were approved by the IACUC, University of Mississippi.
